Publications

Search ACTG publications from 1/1/2006 to current.

Search

Filter results by

Found 62 results
Filters: First Letter Of Title is I  [Clear All Filters]
Found 62 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

I

Williams P, Wu J, Cohn S, et al. "Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution." HIV Med.. 2009;10(5):290-301.
Kshirsagar SA, Blaschke TF, Sheiner LB, Krygowski M, Acosta EP, Verotta D. "Improving data reliability using a non-compliance detection method versus using pharmacokinetic criteria." J Pharmacokinet Pharmacodyn. 2007;34(1):35-55.
Godfrey CC, Michelow PM, Godard M, et al. "Improving diagnostic capability for HPV disease internationally within the NIH-NIAID Division of AIDS Clinical Trial Networks." Am. J. Clin. Pathol.. 2013;140(6):881-9.
Shire NJ, Rao MB, Succop P, et al. "Improving noninvasive methods of assessing liver fibrosis in patients with hepatitis C virus/human immunodeficiency virus co-infection." Clin. Gastroenterol. Hepatol.. 2009;7(4):471-80, 480.e1-2.
Branch AD, Kang M, Hollabaugh K, Wyatt CM, Chung RT, Glesby MJ. "In HIV/hepatitis C virus co-infected patients, higher 25-hydroxyvitamin D concentrations were not related to hepatitis C virus treatment responses but were associated with ritonavir use." Am. J. Clin. Nutr.. 2013;98(2):423-9.
Tsibris AMN, Sagar M, Gulick RM, et al. "In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject." J. Virol.. 2008;82(16):8210-4.
Krishnan S, Schouten JT, Jacobson DL, et al. "Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis." Oncology. 2011;80(1-2):42-9.
Butt AA, Umbleja T, Andersen JW, Chung RT, Sherman KE. "The incidence, predictors and management of anaemia and its association with virological response in HCV / HIV coinfected persons treated with long-term pegylated interferon alfa 2a and ribavirin." Aliment. Pharmacol. Ther.. 2011;33(11):1234-44.
Krishnan S, Wu K, Smurzynski M, et al. "Incidence rate of and factors associated with loss to follow-up in a longitudinal cohort of antiretroviral-treated HIV-infected persons: an AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT) analysis." HIV Clin Trials. 2011;12(4):190-200.
Taylor LE, Holubar M, Wu K, et al. "Incident hepatitis C virus infection among US HIV-infected men enrolled in clinical trials." Clin. Infect. Dis.. 2011;52(6):812-8.
Robbins GK, Spritzler JG, Chan ES, et al. "Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384." Clin. Infect. Dis.. 2009;48(3):350-61.
McComsey GA, Kang M, Ross AC, et al. "Increased mtDNA levels without change in mitochondrial enzymes in peripheral blood mononuclear cells of infants born to HIV-infected mothers on antiretroviral therapy." HIV Clin Trials. 2008;9(2):126-36.
Nielsen-Saines K, Komarow L, Cu-Uvin S, et al. "Infant outcomes after maternal antiretroviral exposure in resource-limited settings." Pediatrics. 2012;129(6):e1525-32.
Mave V, Erlandson KM, Gupte N, et al. "Inflammation and Change in Body Weight With Antiretroviral Therapy Initiation in a Multinational Cohort of HIV-Infected Adults." J. Infect. Dis.. 2016;214(1):65-72.
Venuto CS, Lim J, Messing S, Hunt PW, McComsey GA, Morse GD. "Inflammation investigated as a source of pharmacokinetic variability of atazanavir in AIDS Clinical Trials Group protocol A5224s." Antivir. Ther. (Lond.). 2017.
McComsey GA, Kitch D, Daar ES, et al. "Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or atazanavir/ritonavir." AIDS. 2012;26(11):1371-85.
Pence BWells, Ostermann J, Kumar V, Whetten K, Thielman N, Mugavero MJ. "The influence of psychosocial characteristics and race/ethnicity on the use, duration, and success of antiretroviral therapy." J. Acquir. Immune Defic. Syndr.. 2008;47(2):194-201.
Haubrich RH, Riddler SA, Ribaudo H, et al. "Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection." AIDS. 2011;25(18):2269-78.
Henrich TJ, Ribaudo HJ, Kuritzkes DR. "Instantaneous inhibitory potential is similar to inhibitory quotient at predicting HIV-1 response to antiretroviral therapy." Clin. Infect. Dis.. 2010;51(1):93-8.
Erlandson KM, Fiorillo SP, Cardoso SWagner, et al. "Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation." AIDS Res. Hum. Retroviruses. 2017;33(9):929-934.
Keil K, Hochreitter J, DiFrancesco R, et al. "Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application." Ther Drug Monit. 2007;29(1):103-9.
Gulick RM, Lalama CM, Ribaudo HJ, et al. "Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression." AIDS. 2007;21(7):813-23.
Hu Z, Kuritzkes DR. "Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1." J. Virol.. 2011;85(21):11309-14.
Petersen T, Lee Y-J, Osinusi A, et al. "Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin." AIDS Res. Hum. Retroviruses. 2016;32(7):660-7.
Manion M, Rodriguez B, Medvik K, et al. "Interferon-alpha administration enhances CD8+ T cell activation in HIV infection." PLoS ONE. 2012;7(1):e30306.
Rodriguez B, Lederman MM, Jiang W, et al. "Interferon-alpha differentially rescues CD4 and CD8 T cells from apoptosis in HIV infection." AIDS. 2006;20(10):1379-89.
Vandergeeten C, Fromentin R, DaFonseca S, et al. "Interleukin-7 promotes HIV persistence during antiretroviral therapy." Blood. 2013;121(21):4321-9.
Robertson K, Jiang H, Evans SR, et al. "International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271." J. Neurovirol.. 2016;22(4):472-8.
Skiest DJ, Su Z, Havlir DV, et al. "Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170." J. Infect. Dis.. 2007;195(10):1426-36.
Cummins NW, Jiang W, McGinty J, et al. "Intracellular Casp8p41 content is inversely associated with CD4 T cell count." J. Infect. Dis.. 2010;202(3):386-91.

Pages